| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/14/2001 | WO2001041762A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041761A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041760A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | WO2001041750A2 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| 06/14/2001 | WO2001041747A2 Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer |
| 06/14/2001 | WO2001041743A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | WO2001041704A2 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | WO2001041701A2 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 06/14/2001 | WO2001041536A2 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001041535A2 Eplerenone crystalline form |
| 06/14/2001 | WO2001041534A2 Pseudomycin phosphate prodrugs |
| 06/14/2001 | WO2001028537A3 Bissulfonamide derivatives as enzyme inhibitors |
| 06/14/2001 | WO2001017989A3 Heteroaryloxypropanolamines as beta3-adrenergic receptor agonists |
| 06/14/2001 | WO2001016133A3 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
| 06/14/2001 | WO2001009113A3 Heterocyclic compounds inhibiting angiogenesis |
| 06/14/2001 | WO2001005773A8 Conjugates of sodium channel blockers and methods of using the same |
| 06/14/2001 | WO2001003720A3 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 06/14/2001 | WO2001000812A3 22012, a novel human carboxypeptidase |
| 06/14/2001 | WO2000068255A3 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
| 06/14/2001 | WO2000064441A3 Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| 06/14/2001 | WO2000032631A3 Proteins that bind angiogenesis-inhibiting proteins, compositions and methods of use thereof |
| 06/14/2001 | US20010003782 Novel sterol derivatives used for regulating the meiosis in oocytes and in male germ cells |
| 06/14/2001 | US20010003779 Camptothecin analogs and methods of preparation thereof |
| 06/14/2001 | US20010003752 Crystalline form of 4- [ 5-methyl-3-phenylisoxazol-4-yl ] benzenesulfonamide |
| 06/14/2001 | US20010003750 Used as research tools in pharmacological, diagnostic studies and treatment of diseases in mammals in which 1L-beta-protease activity is implicated; antiinflammatory agent |
| 06/14/2001 | US20010003749 Arylpiperazines having activity at the serotonin 1A receptor |
| 06/14/2001 | US20010003747 Useful in treating or in preventing melatoninergic disorders |
| 06/14/2001 | CA2396739A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | CA2396513A1 Pseudomycin phosphate prodrugs |
| 06/14/2001 | CA2394303A1 Interferon-alpha induced gene |
| 06/14/2001 | CA2394060A1 Transmucosal administration of phosphodiesterase inhibitor for the treatment of erectile dysfunction |
| 06/14/2001 | CA2393859A1 Apoptin-associating protein |
| 06/14/2001 | CA2393779A1 Combination of compounds that inhibit the biological effects of tnf-.alpha. and cd95l in a medicament |
| 06/14/2001 | CA2393748A1 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 06/14/2001 | CA2393661A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393587A1 Use of an immunosuppressant for increasing an antifungal activity of a lipopeptide |
| 06/14/2001 | CA2393532A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | CA2393530A1 Pharmaceutical compositions for oral use |
| 06/14/2001 | CA2393510A1 New (aminopropyl)methylphosphinic acids |
| 06/14/2001 | CA2393470A1 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 06/14/2001 | CA2393463A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 06/14/2001 | CA2393339A1 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| 06/14/2001 | CA2393141A1 Novel methods for the treatment and prevention of ileus |
| 06/14/2001 | CA2393045A1 Mutant er.alpha. and test systems for transactivation |
| 06/14/2001 | CA2392961A1 G-protein coupled receptors |
| 06/14/2001 | CA2392742A1 T1 receptor-like ligand ii and uses thereof |
| 06/14/2001 | CA2392584A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | CA2392568A1 Method for the prevention and/or treatment of atherosclerosis |
| 06/14/2001 | CA2392566A1 4-pyridinyl-n-acyl-l-phenylalanines |
| 06/14/2001 | CA2390093A1 Extracellular matrix and cell adhesion molecules |
| 06/14/2001 | CA2388686A1 Vla-4 integrin antagonists |
| 06/14/2001 | CA2384982A1 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/14/2001 | CA2383001A1 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | CA2362845A1 Eplerenone crystalline form |
| 06/14/2001 | CA2362815A1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | CA2362675A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | CA2362669A1 Eplerenone crystalline form exhibiting enhanced dissolution rate |
| 06/14/2001 | CA2361647A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| 06/13/2001 | EP1106615A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106614A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 06/13/2001 | EP1106612A1 Quinoline derivatives useful for inhibiting farnesyl protein transferase |
| 06/13/2001 | EP1106611A1 Crystalline or crystallized acid addition salt of losartan and purification method of losartan |
| 06/13/2001 | EP1106610A1 Farnesyl transferase inhibiting 2-quinolone derivatives |
| 06/13/2001 | EP1106608A1 Substituted (dihydro)benzoxazine and (dihydro)benzothiazine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 06/13/2001 | EP1106605A1 Alpha1b-adrenergic receptor antagonists |
| 06/13/2001 | EP1106183A2 Antibodies to erbB2 and their therapeutic uses |
| 06/13/2001 | EP1106180A1 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/13/2001 | EP1106179A2 Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
| 06/13/2001 | EP1105738A1 Assays, methods and means for modulating nuclear localisation |
| 06/13/2001 | EP1105518A1 USE OF mCRP FOR DELIVERY OF MATERIALS INTO CELLS |
| 06/13/2001 | EP1105504A1 Cyclophilin-type peptidyl-prolyl cis/trans isomerase |
| 06/13/2001 | EP1105503A2 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE ALPHA1/BETA1 (hsGCALPHA1/BETA1) |
| 06/13/2001 | EP1105485A1 Human il-1 epsilon dna and polypeptides |
| 06/13/2001 | EP1105478A1 Extracellular adhesive proteins, exadh1 and exadh2 |
| 06/13/2001 | EP1105467A1 USE OF MODIFIED LYSOZYME c TO PREPARE MEDICINAL COMPOSITIONS FOR THE TREATMENT OF SOME SERIOUS DISEASES |
| 06/13/2001 | EP1105462A1 Engraftable human neural stem cells |
| 06/13/2001 | EP1105427A2 Generation of modified molecules with increased serum half-lives |
| 06/13/2001 | EP1105422A1 Hepatitis c inhibitor peptides |
| 06/13/2001 | EP1105420A1 Cyclic prosaposin-derived peptides and uses thereof |
| 06/13/2001 | EP1105409A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 06/13/2001 | EP1105408A1 Congugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agents |
| 06/13/2001 | EP1105403A1 3'-desoxypentopyranosyl nucleic acid, its production and its use |
| 06/13/2001 | EP1105393A1 Bicyclic piperidine and piperazine compounds having 5-ht 6? receptor affinity |
| 06/13/2001 | EP1105387A1 Prodrugs of proton pump inhibitors |
| 06/13/2001 | EP1105384A1 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors |
| 06/13/2001 | EP1105378A1 Quinazoline derivatives |
| 06/13/2001 | EP1105377A1 Pyrimidinone derivatives for the treatment of atherosclerosis |
| 06/13/2001 | EP1105370A1 Novel aryl sulphonamides and analogues |
| 06/13/2001 | EP1105159A2 Lt and ct in parenteral immunization methods against helicobacter infection |
| 06/13/2001 | EP1105152A1 Tnf-derived peptides for use in treating oedema |
| 06/13/2001 | EP1105151A1 The use of glial cell line-derived neurotrophic factor family-related compounds for regulating spermatogenesis and for preparing male contraceptives |
| 06/13/2001 | EP1105142A2 Blood-brain barrier therapeutics |
| 06/13/2001 | EP1105141A2 Phosphatidylcholine as a medicament for the protection of mucosa |
| 06/13/2001 | EP1105126A2 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders |
| 06/13/2001 | EP1105124A2 N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders |
| 06/13/2001 | EP1105122A1 Pharmaceutical compositions containing lipase inhibitors |
| 06/13/2001 | EP1105116A1 Hydroxamic acid derivatives as inhibitors of beta-amyloid production |
| 06/13/2001 | EP0958354A4 Thiomethylene group-containing aldehyde cysteine and serine protease inhibitors |
| 06/13/2001 | EP0824527B1 Quinazoline derivatives |
| 06/13/2001 | EP0824526B1 Quinazoline derivative |